메뉴 건너뛰기




Volumn 2014, Issue , 2014, Pages

Radioimmunotherapy: A specific treatment protocol for cancer by cytotoxic radioisotopes conjugated to antibodies

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; AVIDIN; CD20 ANTIBODY; FURAPYRIMIDONE; IBRITUMOMAB TIUXETAN; MONOCLONAL ANTIBODY J591; MUCIN 1; PACLITAXEL; RADIOISOTOPE; STREPTAVIDIN; TOSITUMOMAB I 131; ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; IODINE-131 ANTI-B1 ANTIBODY; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; YTTRIUM;

EID: 84908321303     PISSN: 23566140     EISSN: 1537744X     Source Type: Journal    
DOI: 10.1155/2014/492061     Document Type: Review
Times cited : (53)

References (108)
  • 1
    • 0141865697 scopus 로고    scopus 로고
    • How the field of thyroid endocrinology developed in france after World War II
    • 2-s2.0-0141865697
    • Fragu P., How the field of thyroid endocrinology developed in france after World War II. Bulletin of the History of Medicine 2003 77 2 393 414 10.1353/bhm.2003.0063 2-s2.0-0141865697
    • (2003) Bulletin of the History of Medicine , vol.77 , Issue.2 , pp. 393-414
    • Fragu, P.1
  • 2
    • 84958695064 scopus 로고
    • The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies
    • Pressman D., Korngold L., The in vivo localization of anti-Wagner-osteogenic-sarcoma antibodies. Cancer 1953 6 3 619 623
    • (1953) Cancer , vol.6 , Issue.3 , pp. 619-623
    • Pressman, D.1    Korngold, L.2
  • 5
    • 0025115329 scopus 로고
    • Stable bifunctional chelates of metals used in radiotherapy
    • 2-s2.0-0025115329
    • Moi M. K., DeNardo S. J., Meares C. F., Stable bifunctional chelates of metals used in radiotherapy. Cancer Research 1990 50 3 S789 S793 2-s2.0-0025115329
    • (1990) Cancer Research , vol.50 , Issue.3 , pp. S789-S793
    • Moi, M.K.1    Denardo, S.J.2    Meares, C.F.3
  • 7
    • 64649084383 scopus 로고    scopus 로고
    • Radiation-induced bystander signalling in cancer therapy
    • 2-s2.0-64649084383
    • Prise K. M., O'Sullivan J. M., Radiation-induced bystander signalling in cancer therapy. Nature Reviews Cancer 2009 9 5 351 360 10.1038/nrc2603 2-s2.0-64649084383
    • (2009) Nature Reviews Cancer , vol.9 , Issue.5 , pp. 351-360
    • Prise, K.M.1    O'Sullivan, J.M.2
  • 9
    • 34547121206 scopus 로고    scopus 로고
    • Hypoxia in cancer: Significance and impact on clinical outcome
    • 2-s2.0-34547121206
    • Vaupel P., Mayer A., Hypoxia in cancer: significance and impact on clinical outcome. Cancer and Metastasis Reviews 2007 26 2 225 239 10.1007/s10555-007-9055-1 2-s2.0-34547121206
    • (2007) Cancer and Metastasis Reviews , vol.26 , Issue.2 , pp. 225-239
    • Vaupel, P.1    Mayer, A.2
  • 10
    • 33845977959 scopus 로고    scopus 로고
    • Mitochondrial membrane permeabilization in cell death
    • 2-s2.0-33845977959
    • Kroemer G., Galluzzi L., Brenner C., Mitochondrial membrane permeabilization in cell death. Physiological Reviews 2007 87 1 99 163 10.1152/physrev.00013.2006 2-s2.0-33845977959
    • (2007) Physiological Reviews , vol.87 , Issue.1 , pp. 99-163
    • Kroemer, G.1    Galluzzi, L.2    Brenner, C.3
  • 12
    • 0036494443 scopus 로고    scopus 로고
    • Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication
    • 2-s2.0-0036494443
    • Ganss R., Ryschich E., Klar E., Arnold B., Hämmerling G. J., Combination of T-cell therapy and trigger of inflammation induces remodeling of the vasculature and tumor eradication. Cancer Research 2002 62 5 1462 1470 2-s2.0-0036494443
    • (2002) Cancer Research , vol.62 , Issue.5 , pp. 1462-1470
    • Ganss, R.1    Ryschich, E.2    Klar, E.3    Arnold, B.4    Hämmerling, G.J.5
  • 14
    • 57349122162 scopus 로고    scopus 로고
    • Auger processes in the 21st century
    • 2-s2.0-57349122162
    • Howell R. W., Auger processes in the 21st century. International Journal of Radiation Biology 2008 84 12 959 975 10.1080/09553000802395527 2-s2.0-57349122162
    • (2008) International Journal of Radiation Biology , vol.84 , Issue.12 , pp. 959-975
    • Howell, R.W.1
  • 15
    • 0037083401 scopus 로고    scopus 로고
    • Radionuclide-antibody conjugates for single-cell cytotoxicity
    • 2-s2.0-0037083401
    • Mattes M. J., Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 2002 94 4 1215 1223 10.1002/cncr.10288 2-s2.0-0037083401
    • (2002) Cancer , vol.94 , Issue.4 , pp. 1215-1223
    • Mattes, M.J.1
  • 20
    • 84887362097 scopus 로고    scopus 로고
    • 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma
    • 213Bi radioimmunotherapy with an anti-mCD138 monoclonal antibody in a murine model of multiple myeloma. The Journal of Nuclear Medicine 2013 54 9 1597 1604
    • (2013) The Journal of Nuclear Medicine , vol.54 , Issue.9 , pp. 1597-1604
    • Chérel, M.1    Gouard, S.2    Gaschet, J.3
  • 21
    • 67651168088 scopus 로고    scopus 로고
    • Astatine radiopharmaceuticals: Prospects and problems
    • Vaidyanathan G., Zalutsky M. R., Astatine radiopharmaceuticals: prospects and problems. Current Radiopharmaceuticals 2008 1 3 177 196 10.2174/1874471010801030177
    • (2008) Current Radiopharmaceuticals , vol.1 , Issue.3 , pp. 177-196
    • Vaidyanathan, G.1    Zalutsky, M.R.2
  • 22
    • 46949107981 scopus 로고    scopus 로고
    • Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications
    • 2-s2.0-46949107981
    • Miederer M., Scheinberg D. A., McDevitt M. R., Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications. Advanced Drug Delivery Reviews 2008 60 12 1371 1382 10.1016/j.addr.2008.04.009 2-s2.0-46949107981
    • (2008) Advanced Drug Delivery Reviews , vol.60 , Issue.12 , pp. 1371-1382
    • Miederer, M.1    Scheinberg, D.A.2    McDevitt, M.R.3
  • 24
    • 77955645834 scopus 로고    scopus 로고
    • Design and development of molecular imaging probes
    • 2-s2.0-77955645834
    • Chen K., Chen X., Design and development of molecular imaging probes. Current Topics in Medicinal Chemistry 2010 10 12 1227 1236 10.2174/156802610791384225 2-s2.0-77955645834
    • (2010) Current Topics in Medicinal Chemistry , vol.10 , Issue.12 , pp. 1227-1236
    • Chen, K.1    Chen, X.2
  • 25
    • 78649325858 scopus 로고    scopus 로고
    • Target-specific delivery of peptide-based probes for PET imaging
    • 2-s2.0-78649325858
    • Chen K., Conti P. S., Target-specific delivery of peptide-based probes for PET imaging. Advanced Drug Delivery Reviews 2010 62 11 1005 1022 10.1016/j.addr.2010.09.004 2-s2.0-78649325858
    • (2010) Advanced Drug Delivery Reviews , vol.62 , Issue.11 , pp. 1005-1022
    • Chen, K.1    Conti, P.S.2
  • 26
    • 0016756272 scopus 로고
    • Continuous cultures of fused cells secreting antibody of predefined specificity
    • 2-s2.0-0016756272
    • Köhler G., Milstein C., Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975 256 5517 495 497 10.1038/256495a0 2-s2.0-0016756272
    • (1975) Nature , vol.256 , Issue.5517 , pp. 495-497
    • Köhler, G.1    Milstein, C.2
  • 29
    • 27144550160 scopus 로고    scopus 로고
    • Arming antibodies: Prospects and challenges for immunoconjugates
    • 2-s2.0-27144550160
    • Wu A. M., Senter P. D., Arming antibodies: prospects and challenges for immunoconjugates. Nature Biotechnology 2005 23 9 1137 1146 10.1038/nbt1141 2-s2.0-27144550160
    • (2005) Nature Biotechnology , vol.23 , Issue.9 , pp. 1137-1146
    • Wu, A.M.1    Senter, P.D.2
  • 30
    • 84889848914 scopus 로고    scopus 로고
    • Future prospects of monoclonal antibodies as magic bullets in immunotherapy
    • Maleki L. A., Baradaran B., Majidi J., Future prospects of monoclonal antibodies as magic bullets in immunotherapy. Human Antibodies 2013 22 1-2 9 13
    • (2013) Human Antibodies , vol.22 , Issue.1-2 , pp. 9-13
    • Maleki, L.A.1    Baradaran, B.2    Majidi, J.3
  • 33
    • 74849131675 scopus 로고    scopus 로고
    • Radioimmunotherapy of lymphoma: Bexxar and zevalin
    • 2-s2.0-74849131675
    • Goldsmith S. J., Radioimmunotherapy of lymphoma: bexxar and zevalin. Seminars in Nuclear Medicine 2010 40 2 122 135 10.1053/j.semnuclmed.2009.11.002 2-s2.0-74849131675
    • (2010) Seminars in Nuclear Medicine , vol.40 , Issue.2 , pp. 122-135
    • Goldsmith, S.J.1
  • 35
    • 78650991430 scopus 로고    scopus 로고
    • 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients
    • 2-s2.0-78650991430
    • 131I-rituximab in routine clinical practice: 10-year single-institution experience of 142 consecutive patients. Blood 2011 117 1 45 52 10.1182/blood-2010-02-269753 2-s2.0-78650991430
    • (2011) Blood , vol.117 , Issue.1 , pp. 45-52
    • Leahy, M.F.1    Turner, J.H.2
  • 36
    • 0041761322 scopus 로고    scopus 로고
    • 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: A phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital
    • 2-s2.0-0041761322
    • 131I-anti CD20 radioimmunotherapy of relapsed or refractory non-Hodgkins lymphoma: a phase II clinical trial of a nonmyeloablative dose regimen of chimeric rituximab radiolabeled in a hospital. Cancer Biotherapy & Radiopharmaceuticals 2003 18 4 513 524 10.1089/108497803322287583 2-s2.0-0041761322
    • (2003) Cancer Biotherapy & Radiopharmaceuticals , vol.18 , Issue.4 , pp. 513-524
    • Turner, J.H.1    Martindale, A.A.2    Boucek, J.3    Claringbold, P.G.4    Leahy, M.F.5
  • 42
    • 0038315411 scopus 로고    scopus 로고
    • A comparison of 4 radionuclides conjugated to antibodies for single-cell kill
    • 2-s2.0-0038315411
    • Michel R. B., Brechbiel M. W., Mattes M. J., A comparison of 4 radionuclides conjugated to antibodies for single-cell kill. The Journal of Nuclear Medicine 2003 44 4 632 640 2-s2.0-0038315411
    • (2003) The Journal of Nuclear Medicine , vol.44 , Issue.4 , pp. 632-640
    • Michel, R.B.1    Brechbiel, M.W.2    Mattes, M.J.3
  • 46
    • 0842285646 scopus 로고    scopus 로고
    • Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy
    • 2-s2.0-0842285646
    • Du Y., Honeychurch J., Cragg M. S., Bayne M., Glennie M. J., Johnson P. W. M., Illidge T. M., Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 2004 103 4 1485 1494 10.1182/blood-2003-06-2037 2-s2.0-0842285646
    • (2004) Blood , vol.103 , Issue.4 , pp. 1485-1494
    • Du, Y.1    Honeychurch, J.2    Cragg, M.S.3    Bayne, M.4    Glennie, M.J.5    Johnson, P.W.M.6    Illidge, T.M.7
  • 47
    • 42049087214 scopus 로고    scopus 로고
    • In vitro evaluation of radioprotective and radiosensitizing effects of rituximab
    • 2-s2.0-42049087214
    • Kapadia N. S., Engles J. M., Wahl R. L., In vitro evaluation of radioprotective and radiosensitizing effects of rituximab. The Journal of Nuclear Medicine 2008 49 4 674 678 10.2967/jnumed.107.043752 2-s2.0-42049087214
    • (2008) The Journal of Nuclear Medicine , vol.49 , Issue.4 , pp. 674-678
    • Kapadia, N.S.1    Engles, J.M.2    Wahl, R.L.3
  • 48
    • 50949166628 scopus 로고    scopus 로고
    • Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis
    • 2-s2.0-50949166628
    • Ivanov A., Krysov S., Cragg M. S., Illidge T., Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clinical Cancer Research 2008 14 15 4925 4934 10.1158/1078-0432.CCR-07-5072 2-s2.0-50949166628
    • (2008) Clinical Cancer Research , vol.14 , Issue.15 , pp. 4925-4934
    • Ivanov, A.1    Krysov, S.2    Cragg, M.S.3    Illidge, T.4
  • 52
    • 76549177140 scopus 로고
    • Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques
    • 2-s2.0-76549177140
    • Gold P., Freedman S. O., Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. The Journal of Experimental Medicine 1965 121 439 462 2-s2.0-76549177140
    • (1965) The Journal of Experimental Medicine , vol.121 , pp. 439-462
    • Gold, P.1    Freedman, S.O.2
  • 61
    • 0029832918 scopus 로고    scopus 로고
    • Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy
    • 2-s2.0-0029832918
    • Garin-Chesa P., Sakamoto J., Welt S., Real F. X., Rettig W. J., Old L. J., Organ-specific expression of the colon cancer antigen A33, a cell surface target for antibody-based therapy. International Journal of Oncology 1996 9 3 465 471 2-s2.0-0029832918
    • (1996) International Journal of Oncology , vol.9 , Issue.3 , pp. 465-471
    • Garin-Chesa, P.1    Sakamoto, J.2    Welt, S.3    Real, F.X.4    Rettig, W.J.5    Old, L.J.6
  • 64
    • 34548553392 scopus 로고    scopus 로고
    • 131I-labetuzumab after salvage resection of colorectal liver metastases: Comparison of outcome to a contemporaneous control group
    • 131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Annals of Surgical Oncology 2007 14 9 2577 2590 10.1245/s10434-006-9328-x 2-s2.0-34548553392
    • (2007) Annals of Surgical Oncology , vol.14 , Issue.9 , pp. 2577-2590
    • Liersch, T.1    Meller, J.2    Bittrich, M.3    Kulle, B.4    Becker, H.5    Goldenberg, D.M.6
  • 66
    • 25444439808 scopus 로고    scopus 로고
    • Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol
    • 2-s2.0-25444439808
    • Crow D. M., Williams L., Colcher D., Wong J. Y. C., Raubitschek A., Shively J. E., Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol. Bioconjugate Chemistry 2005 16 5 1117 1125 10.1021/bc0500948 2-s2.0-25444439808
    • (2005) Bioconjugate Chemistry , vol.16 , Issue.5 , pp. 1117-1125
    • Crow, D.M.1    Williams, L.2    Colcher, D.3    Wong, J.Y.C.4    Raubitschek, A.5    Shively, J.E.6
  • 70
    • 0000735189 scopus 로고    scopus 로고
    • Phase i study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer
    • Cagnoni P. J., Ceriani R. L., Cole W. C., Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support (ASCS) in patients with metastatic breast cancer. Cancer Biotherapy & Radiopharmaceuticals 1998 13 4 328
    • (1998) Cancer Biotherapy & Radiopharmaceuticals , vol.13 , Issue.4 , pp. 328
    • Cagnoni, P.J.1    Ceriani, R.L.2    Cole, W.C.3
  • 71
    • 0031281535 scopus 로고    scopus 로고
    • Initial immunochemical characterization of MX35 ovarian cancer antigen
    • 2-s2.0-0031281535
    • Welshinger M., Yin B. W. T., Lloyd K. O., Initial immunochemical characterization of MX35 ovarian cancer antigen. Gynecologic Oncology 1997 67 2 188 192 10.1006/gyno.1997.4846 2-s2.0-0031281535
    • (1997) Gynecologic Oncology , vol.67 , Issue.2 , pp. 188-192
    • Welshinger, M.1    Yin, B.W.T.2    Lloyd, K.O.3
  • 74
    • 26444574248 scopus 로고    scopus 로고
    • Enhancement of the therapeutic index: From nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer
    • 2-s2.0-26444574248
    • DeNardo S. J., Richman C. M., Albrecht H., Burke P. A., Natarajan A., Yuan A., Gregg J. P., O'Donnell R. T., DeNardo G. L., Enhancement of the therapeutic index: from nonmyeloablative and myeloablative toward pretargeted radioimmunotherapy for metastatic prostate cancer. Clinical Cancer Research 2005 11 19 7187s 7194s 10.1158/1078-0432.CCR-1004-0013 2-s2.0-26444574248
    • (2005) Clinical Cancer Research , vol.11 , Issue.19 , pp. 7187s-7194s
    • Denardo, S.J.1    Richman, C.M.2    Albrecht, H.3    Burke, P.A.4    Natarajan, A.5    Yuan, A.6    Gregg, J.P.7    O'Donnell, R.T.8    Denardo, G.L.9
  • 76
    • 23844507146 scopus 로고    scopus 로고
    • High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody
    • 2-s2.0-23844507146
    • Richman C. M., DeNardo S. J., O'Donnell R. T., Yuan A., Shen S., Goldstein D. S., Tuscano J. M., Wun T., Chew H. K., Lara P. N., Kukis D. L., Natarajan A., Meares C. F., Lamborn K. R., DeNardo G. L., High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clinical Cancer Research 2005 11 16 5920 5927 10.1158/1078-0432.CCR-05-0211 2-s2.0-23844507146
    • (2005) Clinical Cancer Research , vol.11 , Issue.16 , pp. 5920-5927
    • Richman, C.M.1    Denardo, S.J.2    O'Donnell, R.T.3    Yuan, A.4    Shen, S.5    Goldstein, D.S.6    Tuscano, J.M.7    Wun, T.8    Chew, H.K.9    Lara, P.N.10    Kukis, D.L.11    Natarajan, A.12    Meares, C.F.13    Lamborn, K.R.14    Denardo, G.L.15
  • 77
    • 4344618391 scopus 로고    scopus 로고
    • Phase i trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer
    • 2-s2.0-4344618391
    • Milowsky M. I., Nanus D. M., Kostakoglu L., Vallabhajosula S., Goldsmith S. J., Bander N. H., Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. Journal of Clinical Oncology 2004 22 13 2522 2531 10.1200/JCO.2004.09.154 2-s2.0-4344618391
    • (2004) Journal of Clinical Oncology , vol.22 , Issue.13 , pp. 2522-2531
    • Milowsky, M.I.1    Nanus, D.M.2    Kostakoglu, L.3    Vallabhajosula, S.4    Goldsmith, S.J.5    Bander, N.H.6
  • 78
    • 22044451179 scopus 로고    scopus 로고
    • 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer
    • 2-s2.0-22044451179
    • 177Lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of Clinical Oncology 2005 23 21 4591 4601 10.1200/JCO.2005.05.160 2-s2.0-22044451179
    • (2005) Journal of Clinical Oncology , vol.23 , Issue.21 , pp. 4591-4601
    • Bander, N.H.1    Milowsky, M.I.2    Nanus, D.M.3    Kostakoglu, L.4    Vallabhajosula, S.5    Goldsmith, S.J.6
  • 81
    • 0022469060 scopus 로고
    • Monoclonal antibody hapten radiopharmaceutical delivery
    • 2-s2.0-0022469060
    • Goodwin D. A., Mears C. F., McTigue M., David G. S., Monoclonal antibody hapten radiopharmaceutical delivery. Nuclear Medicine Communications 1986 7 8 569 580 10.1097/00006231-198608000-00002 2-s2.0-0022469060
    • (1986) Nuclear Medicine Communications , vol.7 , Issue.8 , pp. 569-580
    • Goodwin, D.A.1    Mears, C.F.2    McTigue, M.3    David, G.S.4
  • 82
    • 0023841413 scopus 로고
    • Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
    • 2-s2.0-0023841413
    • Goodwin D. A., Meares C. F., McCall M. J., McTigue M., Chaovapong W., Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens. The Journal of Nuclear Medicine 1988 29 2 226 234 2-s2.0-0023841413
    • (1988) The Journal of Nuclear Medicine , vol.29 , Issue.2 , pp. 226-234
    • Goodwin, D.A.1    Meares, C.F.2    McCall, M.J.3    McTigue, M.4    Chaovapong, W.5
  • 83
    • 33644869654 scopus 로고    scopus 로고
    • Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy
    • 2-s2.0-33644869654
    • Goldenberg D. M., Sharkey R. M., Paganelli G., Barbet J., Chatal J., Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. Journal of Clinical Oncology 2006 24 5 823 834 10.1200/JCO.2005.03.8471 2-s2.0-33644869654
    • (2006) Journal of Clinical Oncology , vol.24 , Issue.5 , pp. 823-834
    • Goldenberg, D.M.1    Sharkey, R.M.2    Paganelli, G.3    Barbet, J.4    Chatal, J.5
  • 85
    • 0023619395 scopus 로고
    • Investigations of avidin and biotin for imaging applications
    • 2-s2.0-0023619395
    • Hnatowich D. J., Virzi F., Rusckowski M., Investigations of avidin and biotin for imaging applications. The Journal of Nuclear Medicine 1987 28 8 1294 1302 2-s2.0-0023619395
    • (1987) The Journal of Nuclear Medicine , vol.28 , Issue.8 , pp. 1294-1302
    • Hnatowich, D.J.1    Virzi, F.2    Rusckowski, M.3
  • 88
    • 0034541209 scopus 로고    scopus 로고
    • A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy
    • 2-s2.0-0034541209
    • Schultz J., Lin Y., Sanderson J., Zuo Y., Stone D., Mallett R., Wilbert S., Axworthy D., A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Research 2000 60 23 6663 6669 2-s2.0-0034541209
    • (2000) Cancer Research , vol.60 , Issue.23 , pp. 6663-6669
    • Schultz, J.1    Lin, Y.2    Sanderson, J.3    Zuo, Y.4    Stone, D.5    Mallett, R.6    Wilbert, S.7    Axworthy, D.8
  • 89
    • 0037569482 scopus 로고    scopus 로고
    • Radioimmunotherapy: Is avidin-biotin pretargeting the preferred choice among pretargeting methods?
    • 2-s2.0-0037569482
    • Paganelli G., Chinol M., Radioimmunotherapy: is avidin-biotin pretargeting the preferred choice among pretargeting methods? European Journal of Nuclear Medicine and Molecular Imaging 2003 30 5 773 776 2-s2.0-0037569482
    • (2003) European Journal of Nuclear Medicine and Molecular Imaging , vol.30 , Issue.5 , pp. 773-776
    • Paganelli, G.1    Chinol, M.2
  • 93
    • 0024395317 scopus 로고
    • In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: Enhanced divalent hapten affinity for cell-bound antibody conjugate
    • 2-s2.0-0024395317
    • le Doussal J.-M., Martin M., Gautherot E., Delaage M., Barbet J., In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate. The Journal of Nuclear Medicine 1989 30 8 1358 1366 2-s2.0-0024395317
    • (1989) The Journal of Nuclear Medicine , vol.30 , Issue.8 , pp. 1358-1366
    • Le Doussal, J.-M.1    Martin, M.2    Gautherot, E.3    Delaage, M.4    Barbet, J.5
  • 96
    • 27744440557 scopus 로고    scopus 로고
    • Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft
    • 2-s2.0-27744440557
    • Karacay H., Brard P., Sharkey R. M., Chang C., Rossi E. A., McBride W. J., Ragland D. R., Horak I. D., Goldenberg D. M., Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clinical Cancer Research 2005 11 21 7879 7885 10.1158/1078-0432.CCR-05-1246 2-s2.0-27744440557
    • (2005) Clinical Cancer Research , vol.11 , Issue.21 , pp. 7879-7885
    • Karacay, H.1    Brard, P.2    Sharkey, R.M.3    Chang, C.4    Rossi, E.A.5    McBride, W.J.6    Ragland, D.R.7    Horak, I.D.8    Goldenberg, D.M.9
  • 100
    • 62449328137 scopus 로고    scopus 로고
    • Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma
    • 2-s2.0-62449328137
    • Sharkey R. M., Karacay H., Johnson C. R., Litwin S., Rossi E. A., Mebride W. J., Chang C., Goldenberg D. M., Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. The Journal of Nuclear Medicine 2009 50 3 444 453 10.2967/jnumed.108.058602 2-s2.0-62449328137
    • (2009) The Journal of Nuclear Medicine , vol.50 , Issue.3 , pp. 444-453
    • Sharkey, R.M.1    Karacay, H.2    Johnson, C.R.3    Litwin, S.4    Rossi, E.A.5    Mebride, W.J.6    Chang, C.7    Goldenberg, D.M.8
  • 101
    • 48549083845 scopus 로고    scopus 로고
    • Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody
    • 2-s2.0-48549083845
    • Sharkey R. M., Karacay H., Litwin S., Rossi E. A., McBride W. J., Chang C., Goldenberg D. M., Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Research 2008 68 13 5282 5290 10.1158/0008-5472.CAN-08-0037 2-s2.0-48549083845
    • (2008) Cancer Research , vol.68 , Issue.13 , pp. 5282-5290
    • Sharkey, R.M.1    Karacay, H.2    Litwin, S.3    Rossi, E.A.4    McBride, W.J.5    Chang, C.6    Goldenberg, D.M.7
  • 103
    • 66549084591 scopus 로고    scopus 로고
    • A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations
    • 2-s2.0-66549084591
    • Pagel J. M., Orgun N., Hamlin D. K., Wilbur D. S., Gooley T. A., Gopal A. K., Park S. I., Green D. J., Lin Y., Press O. W., A comparative analysis of conventional and pretargeted radioimmunotherapy of B-cell lymphomas by targeting CD20, CD22, and HLA-DR singly and in combinations. Blood 2009 113 20 4903 4913 10.1182/blood-2008-11-187401 2-s2.0-66549084591
    • (2009) Blood , vol.113 , Issue.20 , pp. 4903-4913
    • Pagel, J.M.1    Orgun, N.2    Hamlin, D.K.3    Wilbur, D.S.4    Gooley, T.A.5    Gopal, A.K.6    Park, S.I.7    Green, D.J.8    Lin, Y.9    Press, O.W.10
  • 104
    • 19644371098 scopus 로고    scopus 로고
    • Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies
    • 2-s2.0-19644371098
    • Shen S., Forero A., LoBuglio A. F., Breitz H., Khazaeli M. B., Fisher D. R., Wang W., Meredith R. F., Patient-specific dosimetry of pretargeted radioimmunotherapy using CC49 fusion protein in patients with gastrointestinal malignancies. The Journal of Nuclear Medicine 2005 46 4 642 651 2-s2.0-19644371098
    • (2005) The Journal of Nuclear Medicine , vol.46 , Issue.4 , pp. 642-651
    • Shen, S.1    Forero, A.2    Lobuglio, A.F.3    Breitz, H.4    Khazaeli, M.B.5    Fisher, D.R.6    Wang, W.7    Meredith, R.F.8
  • 106
    • 0030731858 scopus 로고    scopus 로고
    • Low-dose radiation sensitivity and induced radioresistance to cell killing in HT-29 cells is distinct from the 'adaptive response' and cannot be explained by a subpopulation of sensitive cells
    • 2-s2.0-0030731858
    • Wouters B. G., Skarsgard L. D., Low-dose radiation sensitivity and induced radioresistance to cell killing in HT-29 cells is distinct from the 'adaptive response' and cannot be explained by a subpopulation of sensitive cells. Radiation Research 1997 148 5 435 442 10.2307/3579320 2-s2.0-0030731858
    • (1997) Radiation Research , vol.148 , Issue.5 , pp. 435-442
    • Wouters, B.G.1    Skarsgard, L.D.2
  • 108
    • 0031909654 scopus 로고    scopus 로고
    • A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85
    • Overgaard J., Hansen H. S., Overgaard M., Bastholt L., Berthelsen A., Specht L., Lindeløv B., Jørgensen K., A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and Oncology 1998 46 2 135 146 10.1016/S0167-8140(97)00220-X 2-s2.0-0031909654
    • (1998) Radiotherapy and Oncology , vol.46 , Issue.2 , pp. 135-146
    • Overgaard, J.1    Hansen, H.S.2    Overgaard, M.3    Bastholt, L.4    Berthelsen, A.5    Specht, L.6    Lindeløv, B.7    Jørgensen, K.8


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.